Zacks Research Issues Pessimistic Estimate for PBYI Earnings

Puma Biotechnology, Inc. (NASDAQ:PBYI) – Research analysts at Zacks Research reduced their FY2024 earnings per share (EPS) estimates for shares of Puma Biotechnology in a report released on Thursday, January 9th. Zacks Research analyst R. Department now forecasts that the biopharmaceutical company will post earnings per share of $0.31 for the year, down from their prior estimate of $0.32. The consensus estimate for Puma Biotechnology’s current full-year earnings is $0.31 per share. Zacks Research also issued estimates for Puma Biotechnology’s Q1 2025 earnings at $0.03 EPS, Q4 2025 earnings at $0.13 EPS, Q1 2026 earnings at $0.01 EPS, Q3 2026 earnings at $0.12 EPS, Q4 2026 earnings at $0.07 EPS and FY2026 earnings at $0.25 EPS.

Puma Biotechnology (NASDAQ:PBYI) last issued its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported $0.41 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.31 by $0.10. The business had revenue of $80.50 million for the quarter, compared to the consensus estimate of $71.32 million. Puma Biotechnology had a return on equity of 41.60% and a net margin of 9.56%. During the same period in the prior year, the firm posted $0.12 earnings per share.

Several other equities research analysts have also commented on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price target on shares of Puma Biotechnology in a report on Monday, December 23rd. StockNews.com cut shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research note on Friday, December 6th.

Puma Biotechnology Trading Down 6.8 %

Shares of NASDAQ:PBYI opened at $3.31 on Monday. The business has a 50-day moving average price of $3.06 and a 200-day moving average price of $2.99. The stock has a market cap of $162.48 million, a price-to-earnings ratio of 6.90 and a beta of 1.10. Puma Biotechnology has a 52-week low of $2.22 and a 52-week high of $7.73. The company has a quick ratio of 1.40, a current ratio of 1.42 and a debt-to-equity ratio of 0.46.

Insiders Place Their Bets

In other Puma Biotechnology news, insider Jeffrey Jerome Ludwig sold 9,437 shares of the company’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $3.15, for a total transaction of $29,726.55. Following the transaction, the insider now directly owns 108,951 shares in the company, valued at $343,195.65. This represents a 7.97 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Alan H. Auerbach sold 33,841 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $3.15, for a total value of $106,599.15. Following the transaction, the chief executive officer now owns 7,029,674 shares of the company’s stock, valued at $22,143,473.10. This trade represents a 0.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 23.70% of the company’s stock.

Institutional Investors Weigh In On Puma Biotechnology

A number of hedge funds have recently bought and sold shares of PBYI. Los Angeles Capital Management LLC purchased a new position in shares of Puma Biotechnology during the third quarter worth about $627,000. FMR LLC increased its stake in Puma Biotechnology by 27.1% in the 3rd quarter. FMR LLC now owns 118,265 shares of the biopharmaceutical company’s stock valued at $302,000 after buying an additional 25,183 shares during the period. Barclays PLC increased its stake in shares of Puma Biotechnology by 146.5% during the third quarter. Barclays PLC now owns 78,021 shares of the biopharmaceutical company’s stock worth $199,000 after acquiring an additional 46,370 shares during the period. Franklin Resources Inc. purchased a new position in shares of Puma Biotechnology during the 3rd quarter worth approximately $41,000. Finally, Affinity Asset Advisors LLC purchased a new position in Puma Biotechnology in the second quarter worth $815,000. Institutional investors and hedge funds own 61.29% of the company’s stock.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.